VX12-809-105 CF Rollover study

• Research type

  Research Study

• Full title

  A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

• IRAS ID

  125768

• Contact name

  Jane Davies

• Contact email

  j.c.davies@imperial.ac.uk

• Sponsor organisation

  Vertex Pharmaceuticals Incorporated

• Eudract number

  2013-000604-41

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  13/SC/0452

• Date of REC Opinion

  1 Oct 2013

• REC opinion

  Favourable Opinion